Brian Foard — Global Business Unit Head, Specialty Care:
“I think from an environment standpoint, the Inflation Reduction Act, there’s a couple of things in there. And as we’ve said before, our position is, it’s not really good for innovation just in general, the Inflation Reduction Act.”
All entries for: Sanofi
October 25, 2024
Sanofi
Negative Outlook
Paris, France
50,001+ employees
50001+ employees
Disease Area: Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
October 28, 2022
Sanofi
Neutral Outlook
Paris, France
50,001+ employees
50001+ employees
SA CO Paul Hudson stated that the IRA “…will likely create significant uncertainties across our industry,” highlighting investments into future R&D. However, Mr. Hudson noted that SA is “well positioned in the short term” to navigate IRA challenges. 1. And that the orphan drug exemption to price setting is only applicable to drugs with only one indication, which disincentivizes pursuing additional indications 2. The discrepancy between the eligibility dates of biologics and small-molecule drugs for price setting
Disease Area: Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
